ArticleDiscover oncology2026
Analysis of prognostic factors and construction of a nomogram for patients with brain metastases from cancer of unknown primary based on the SEER database.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCancer of unknown primary with brain metastases (CUP-BM) represents a distinct and challenging disease entity characterized by an extremely poor prognosis. Currently, there is a lack of systematic research on its prognostic factors. This study aimed to analyze the prognostic factors associated with CUP-BM.
methodsPatients diagnosed with CUP-BM between 2010 and 2022 were identified from the SEER database. Kaplan-Meier survival curves were utilized to analyze survival differences among various histological subtypes. Univariate and multivariate Cox proportional hazards regression analyses were employed to identify prognostic factors and construct a prognostic nomogram model. Subgroup analysis was conducted to assess the robustness of age as a prognostic factor and explore potential interaction effects with other variables.
resultsA total of 700 eligible CUP-BM patients were included. The neuroendocrine subtype demonstrated the most favorable prognosis. Multivariate analysis revealed that histological type, chemotherapy, liver metastasis, lung metastasis, bone metastasis, and age were independent prognostic factors for overall survival (OS). The constructed nomogram exhibited satisfactory predictive performance (bias-corrected C-index = 0.663). Subgroup analysis showed that age remained a significant prognostic factor in most clinical strata, although its effect varied across subgroups defined by metastatic burden and histological subtype.
conclusionNeuroendocrine histology and chemotherapy were associated with improved survival, while adenocarcinoma histology, age greater than 60 years, and the presence of liver, lung, or bone metastasis were identified as poor prognostic factors for CUP-BM. The nomogram exhibited good calibration and discrimination capability for prognostic prediction in CUP-BM patients. Notably, the prognostic impact of age was substantially attenuated in patients with extensive metastatic burden, highlighting the importance of individualized risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.